Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...
7don MSN
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...
Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...
Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...
All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of Wednesday, raising the ...
The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday, as lawmakers ...
Hosted on MSN1mon
Novo Nordisk is bigger than Denmark's economy — but the prime minister isn't worried about another NokiaThe logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters in Bagsvaerd outside of Copenhagen, Denmark on February 1, 2017. Denmark Prime Minister Mette Frederiksen ...
Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).
Novo Nordisk controls 55% of the GLP-1 market, driven by Ozempic and Wegovy. The concern is that if Novo Nordisk acquires Catalent, it could gain unprecedented access to Eli Lilly's production ...
In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has been actively engaged in a share repurchase program, aiming to buy back B shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback